Hyper-multicolor High-content Cellular Assay Based On Quantum Dot Nanoprobe | 34539
Journal of Analytical & Bioanalytical Techniques
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
High-Content Cell-Based Assay (HCA) has attracted great attention due to its ability to be used in the drug discovery-driven
research and development required to understand the functions of genes and gene products at the level of the cell. HCA
simultaneously measures multiple biomarkers in a single cell with multiplexing fluorescent probes. The complex intracellular
responses involved in drug-induced efficacy or cytotoxicity can be observed in organ-specific cells by HCA. Application of HCA
to organ-specific cell models provides deeper biological information suitable for better decisions on progressing compounds. Early
safety evaluation by HCA reveals the complex cellular responses triggered by potentially harmful molecules in the cells of target
organs. Gaining a deep understanding of the mechanisms underlying these cellular toxicological responses is valuable before a series
of lead compounds are progressed to time-consuming and expensive animal tests. Despite HCA’s capability, it is not common to
simultaneously observe many biomarkers in an intact cell. This is because HCA measurement is dependent on the use of probing
materials. Concurrent monitoring of multiple biomarkers is practically limited due to the spectral overlap among probing materials
having broad absorption and emission spectrums. Quantum dot-based HCA is capable of supplying cellular imaging at particular
wavelengths and each wavelength can be scanned rapidly. This cellular imaging is very advantageous in that it can select particular
wavelengths that do not overlap among the probing materials and concurrently monitor a large number of drug targets or biomarkers.
Joon Myong Song received his PhD in 1997 at Kyushu University, in Japan. He worked as a Postdoctoral Research Fellow from 1998 to 2004 at Iowa State University, Brookhaven National Laboratory, and Oak Ridge National Laboratory in United States. At present, he is a Professor and Head of Department of Pharmacy at College of Pharmacy School, Seoul National University in South Korea. His research area includes multifunctional nanoparticle for diagnosis and therapy and high-content cell-based drug screening and diagnosis using hyper-multicolor cellular imaging. He has published 84 peer reviewed papers in the top journals, 7 book chapters, and 10 patents.